Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_assertion type Assertion NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_head.
- NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_assertion description "[We investigate here the mechanisms by which in vivo abrogation of leptin effects protects SJL/J mice from proteolipid protein peptide PLP(139-151)-induced EAE, an animal model of MS. Blockade of leptin with anti-leptin Abs or with a soluble mouse leptin receptor chimera (ObR:Fc), either before or after onset of EAE, improved clinical score, slowed disease progression, reduced disease relapses, inhibited PLP(139-151)-specific T cell proliferation, and switched cytokine secretion toward a Th2/regulatory profile.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_provenance.
- NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_assertion evidence source_evidence_literature NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_provenance.
- NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_assertion SIO_000772 16410832 NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_provenance.
- NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_assertion wasDerivedFrom befree-20150227 NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_provenance.
- NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_assertion wasGeneratedBy ECO_0000203 NP658780.RAqFIL8aR_ptc_i_6rKs2syRSkzMKk57bdG8DbiN5ZvfU130_provenance.